Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial
eClinicalMedicine · 16 authors, 8 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The primary clinical outcome of death, MI, stroke, or revascularization at 3 years was comparable between strategies, both in patients with and without diabetes.
Full summary
649 CHARS
This is a pre-specified subgroup analysis from the LODESTAR randomized controlled trial. The primary outcome was a 3-year composite of all-cause death, myocardial infarction, stroke, or coronary revascularization. For secondary outcomes, among patients without DM, the treat-to-target strategy was associated with a significantly lower risk of new-onset diabetes requiring medication (5.1% vs 7.4%, HR 0.68) and a trend toward lower risk of any new-onset diabetes. The study has a median follow-up of 3.0 years. A limitation noted is the slightly higher proportion of chronic kidney disease in the high-intensity statin group among patients with DM.
